<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03225846</url>
  </required_header>
  <id_info>
    <org_study_id>WVE-HDSNP2-001</org_study_id>
    <nct_id>NCT03225846</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease</brief_title>
  <acronym>PRECISION-HD2</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wave Life Sciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wave Life Sciences Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRECISION-HD2 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled
      study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)
      of single and multiple doses of WVE-120102 in adult patients with early manifest Huntington's
      disease (HD) who carry a targeted single nucleotide polymorphism (SNP) rs362331 (SNP2).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Number of patients with adverse events (AEs)</measure>
    <time_frame>Day 1 to Day 210 (end of study)</time_frame>
    <description>All AEs reported or observed during the study, including AEs resulting from concurrent illnesses, reactions to concurrent medications, or progression of disease states</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Severity of AEs</measure>
    <time_frame>Day 1 to Day 210 (end of study)</time_frame>
    <description>Severity will be evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Number of patients with serious AEs (SAEs)</measure>
    <time_frame>Day 1 to Day 210 (end of study)</time_frame>
    <description>An SAE is defined as any event that results in death, is immediately life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect not present at Prescreening.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability: Number of patients who withdraw due to AEs</measure>
    <time_frame>Day 1 to Day 210 (end of study)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum observed concentration (Cmax)</measure>
    <time_frame>Day 1 to Day 196</time_frame>
    <description>Cmax of WVE-120102 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time of occurrence of Cmax (tmax)</measure>
    <time_frame>Day 1 to Day 196</time_frame>
    <description>tmax of WVE-120102 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area under the plasma concentration-time curve (AUC 0-t)</measure>
    <time_frame>Day 1 to Day 196</time_frame>
    <description>AUC 0-t from time zero to the last quantifiable concentration of WVE-120102 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Terminal elimination rate constant</measure>
    <time_frame>Day 1 to Day 196</time_frame>
    <description>Elimination rate of WVE-120102 from plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD)</measure>
    <time_frame>Day 1 to Day 196</time_frame>
    <description>Concentration of mutant huntingtin (mHTT) protein in CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Effects: Total Functional Capacity (TFC)</measure>
    <time_frame>Day 1 to Day 140</time_frame>
    <description>Change from baseline to the last measured time point (Day 140) and difference from placebo in the TFC, administered as part of the Unified Huntington's Disease Rating Scale (UHDRS).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>UHDRS</measure>
    <time_frame>Day 1 to Day 140</time_frame>
    <description>Change from baseline to the last measured time point (Day 140) and difference from placebo in the UHDRS</description>
  </other_outcome>
  <other_outcome>
    <measure>Short Problems Behavior Assessment (PBA-s)</measure>
    <time_frame>Day 1 to Day 140</time_frame>
    <description>Change from baseline to the last measured time point (Day 140) and difference from placebo in the PBA-s</description>
  </other_outcome>
  <other_outcome>
    <measure>Magnetic Resonance Imaging</measure>
    <time_frame>Screening to Day 140</time_frame>
    <description>Changes from baseline MRI of the brain.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Huntington's Disease</condition>
  <arm_group>
    <arm_group_label>WVE-120102 (Dose A) or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WVE-120102 (Dose B) or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WVE-120102 (Dose C) or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WVE-120102 (Dose D) or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WVE-120102</intervention_name>
    <description>WVE-120102 is a stereopure antisense oligonucleotide (ASO)</description>
    <arm_group_label>WVE-120102 (Dose A) or placebo</arm_group_label>
    <arm_group_label>WVE-120102 (Dose B) or placebo</arm_group_label>
    <arm_group_label>WVE-120102 (Dose C) or placebo</arm_group_label>
    <arm_group_label>WVE-120102 (Dose D) or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% Sodium Chloride</description>
    <arm_group_label>WVE-120102 (Dose A) or placebo</arm_group_label>
    <arm_group_label>WVE-120102 (Dose B) or placebo</arm_group_label>
    <arm_group_label>WVE-120102 (Dose C) or placebo</arm_group_label>
    <arm_group_label>WVE-120102 (Dose D) or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Prescreened with targeted SNP on the same allele as the pathogenic CAG expansion

          -  Ambulatory, male or female patients aged ≥25 - ≤65 years

          -  Clinical diagnostic motor features of HD, defined as Unified Huntington's Disease
             Rating Scale (UHDRS) Diagnostic Confidence Score = 4

          -  Early manifest HD, Stage I or Stage II based on UHDRS Total Functional Capacity Scores
             ≥7 and ≤13

        Key Exclusion Criteria:

          -  Malignancy or received treatment for malignancy, other than treated basal cell or
             squamous cell carcinoma of the skin, within the previous 5 years

          -  Received investigational drug or implantable device in prior 3 months or
             investigational oligonucleotide in prior 6 months or 5 halflives of the
             oligonucleotide, whichever is longer

          -  Clinically significant medical condition, unstable psychiatric symptoms, substance
             abuse, or pregnancy

          -  Inability to undergo brain MRI

          -  Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or
             unsuccessful lumbar puncture
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serena Hung, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wave Life Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Operations</last_name>
    <phone>855-215-4687</phone>
    <email>clinicaltrials@wavelifesci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre For Movement Disorders</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Guttman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Sw. Wojciecha</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-462</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jaroslaw Slawek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instytut Psychiatrii i Neurologii</name>
      <address>
        <city>Warsaw</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Grzegorz Witkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

